サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：コンパニオン診断の世界市場規模調査＆予測、技術別、適応症別、エンドユーザー別、地域別分析、2022-2029年
市場調査レポート
商品コード
1269698

コンパニオン診断の世界市場規模調査＆予測、技術別、適応症別、エンドユーザー別、地域別分析、2022-2029年

Global Companion Diagnostics Market Size study & Forecast, by Technology by Indication, By End User and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
コンパニオン診断の世界市場規模調査＆予測、技術別、適応症別、エンドユーザー別、地域別分析、2022-2029年
出版日: 2023年05月05日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コンパニオン診断の世界市場は、2021年に約68億米ドルと評価され、予測期間2022-2029年には11.0%以上の健全な成長率で成長すると予測されています。

コンパニオン診断は、同等の生物学的製剤や医薬品の使用が安全かつ効果的であることを確認するために使用される検査です。これらの検査は、通常、がんの診断に使用されます。この検査では、特定されたバイオマーカーに基づいて、適切な医薬品が推奨されます。特定の患者の反応に基づき、これらの検査は個別化された治療を提供します。コンパニオン診断市場は、がんの発生率の増加や、さまざまな適応症に対する新検査の認可の増加などの要因によって拡大しつつあります。

世界のがんの有病率の上昇が市場の成長を促進しており、2022年2月に世界保健機関（WHO）が発表した統計によると、世界中で毎年約40万人の子供ががんを発症しています。国際がん研究機関の推計では、2040年までに世界で新たに発生するがんは2,750万件に増加するとされています。世界のがん罹患率の上昇に伴い、これらの検査の利用が増加しており、市場の拡大を後押ししています。また、これらの検査が様々な適応症で規制当局から承認されることで、市場の拡大が予想されます。例えば、2022年8月、米国FDAはThermo Fisher Scientific Inc.のOncomine Dx Target Testをコンパニオン診断（CDx）として承認しました。このテストは、HER2（ERBB2）活性化変異（SNVs &Exon 20 Insertion）を示す非小細胞肺がん腫瘍を特定します。また、医薬品と診断技術の共同開発や政府の有利な支援により、市場は有利な成長を遂げています。しかし、医薬品開発とそれに伴う臨床試験のコストが高いため、市場の成長が阻害される可能性があります。

コンパニオン診断の世界市場調査において考慮した主な地域は、アジア太平洋地域、北米、欧州、中南米、その他の地域です。北米は、創薬活動の活発化、疾患の有病率の上昇、規制当局の承認取得の増加により、売上高で市場を独占しています。一方、アジア太平洋地域は、疾病の蔓延、医薬品開発のための共同研究の増加、主要参入企業の地域的拡大、政府機関や非営利団体の市場参入などの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、競合情勢や主要企業の技術提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界・セグメント別市場推定・予測、2019年～2029年
    • コンパニオン診断市場、地域別、2019-2029年
    • コンパニオン診断市場、技術別、2019-2029年
    • コンパニオン診断市場、適応症別、2019-2029年
    • コンパニオン診断市場、エンドユーザー別、2019-2029年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 コンパニオン診断の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 本調査の対象となった年
  • 通貨換算レート

第3章 コンパニオン診断の世界市場力学

  • コンパニオン診断市場のインパクト分析（2019-2029年）
    • 市場促進要因
      • がん罹患率の増加
      • 適応症に応じた新検査の承認取得が進む
    • 市場の課題
      • 医薬品開発および関連する臨床試験の高いコスト
    • 市場機会
      • 医薬品と診断技術の共同開発
      • 政府による前向きなサポート

第4章 コンパニオン診断の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • ソーシャル
    • テクニカル
  • 主な投資機会
  • 主要成功戦略
  • 業界関係者見通し
  • アナリストの提言と結論

第5章 リスク評価：COVID-19の影響

  • COVID-19が業界に与える全体的な影響についての評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 コンパニオン診断の世界市場：技術別

  • マーケットスナップショット
  • コンパニオン診断の世界市場：技術別、業績別- ポテンシャル分析
  • コンパニオン診断の世界市場技術別推定・予測2019-2029
  • コンパニオン診断市場、サブセグメント分析
    • 免疫組織化学（IHC）
    • ポリメラーゼ連鎖反応（PCR）
    • インサイチュハイブリダイゼーション（ISH）
    • リアルタイムPCR（RT-PCR）
    • 遺伝子配列決定
    • その他の技術

第7章 コンパニオン診断の世界市場：適応症別

  • マーケットスナップショット
  • コンパニオン診断の世界市場：適応症別、業績別-潜在能力分析
  • コンパニオン診断の世界市場、適応症別推定・予測2019-2029
  • コンパニオン診断市場、サブセグメント分析
    • 肺がん
    • 乳がん
    • 大腸がん
    • 白血病
    • メラノーマ
    • その他の適応症

第8章 コンパニオン診断の世界市場：エンドユーザー別

  • マーケットスナップショット
  • コンパニオン診断の世界市場：エンドユーザー別）、実績 - ポテンシャル分析
  • コンパニオン診断の世界市場推定・予測（エンドユーザー別） 2019-2029
  • コンパニオン診断市場、サブセグメント分析
    • 製薬会社・バイオ医薬品会社
    • レファレンスラボ
    • CRO
    • その他

第9章 コンパニオン診断の世界市場：地域別分析

  • コンパニオン診断市場、地域別市場スナップショット
  • 北米
    • 米国
      • 技術別の推定・予測、2019年～2029年
      • 適応症別の推定・予測、2019年～2029年
      • エンドユーザー別の推定・予測、2019年～2029年
    • カナダ
  • 欧州コンパニオン診断市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋のコンパニオン診断市場のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカコンパニオン診断市場スナップショット
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 世界のその他の地域

第10章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Abbott Laboratories
      • 主要な情報
      • 概要
      • 財務（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • Agilent Technologies Inc.
    • F.Hoffmann-La Roche Ltd
    • Biomerieux SA
    • Qiagen NV
    • Siemens Healthcare Gmbh
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation（Beckman Coulter Inc.）
    • Almac Group
    • Illumina Inc.

第11章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Companion Diagnostics Market, report scope
  • TABLE 2. Global Companion Diagnostics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Companion Diagnostics Market estimates & forecasts by Technology 2019-2029 (USD Billion)
  • TABLE 4. Global Companion Diagnostics Market estimates & forecasts by Indication 2019-2029 (USD Billion)
  • TABLE 5. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Companion Diagnostics Market
  • TABLE 70. List of primary sources, used in the study of global Companion Diagnostics Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Companion Diagnostics Market, research methodology
  • FIG 2. Global Companion Diagnostics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Companion Diagnostics Market, key trends 2021
  • FIG 5. Global Companion Diagnostics Market, growth prospects 2022-2029
  • FIG 6. Global Companion Diagnostics Market, porters 5 force model
  • FIG 7. Global Companion Diagnostics Market, pest analysis
  • FIG 8. Global Companion Diagnostics Market, value chain analysis
  • FIG 9. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Companion Diagnostics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Companion Diagnostics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Companion Diagnostics Market is valued at approximately USD 6.80 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.0% over the forecast period 2022-2029. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer. In this, an appropriate medicine is recommended based on the identified biomarker. Based on a particular patient's response, these tests offer personalized treatment. The Companion Diagnostics market is expanding because of factors such as the increasing incidence of Cancer and rising Regulatory Approvals of New Tests for Different Indications.

The rising prevalence of cancer globally is fostering market growth, according to statistics published by the World Health Organization (WHO) in February 2022, approximately 400,000 children develop cancer worldwide every year. Also, according to the statistics published by the World Cancer Research Fund International, in 2020, there were 18,094,716 million cases of cancer diagnosed globally. The International Agency for Research on Cancer estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040. The usage of these tests is increasing due to the increased incidence of cancer worldwide, which is boosting the market's expansion. Also, it is anticipated that regulatory approvals of these tests for various indications will expand the market. For instance, in August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test as a companion diagnostic (CDx). This test identifies non-small cell lung cancer tumours that exhibit HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion). In addition, the co-development of drug and diagnostic technology and favorable government support is creating lucrative growth in the market. However, the high cost of drug development and associated clinical trials may halt market growth.

The key regions considered for the Global Companion Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising drug discovery activities, rising prevalence of diseases and rising regulatory approvals in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease prevalence, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • F.Hoffmann-La Roche Ltd
  • Biomerieux SA
  • Qiagen NV
  • Siemens Healthcare Gmbh
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Beckman Coulter Inc.)
  • Almac Group
  • Illumina Inc.

Recent Developments in the Market:

  • In January 2022, Amoy Diagnostics Co. Ltd., and PREMIA Holdings (HK) Limited introduced the AmoyDx Pan Lung Cancer PCR Panel (the "PLC Panel") in Japan as a reimbursed companion diagnostic for various anti-cancer drugs.
  • In January 2021,In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings unveiled OmniSeq INSIGHTsm, a complete tissue-based test for genomic and immunological profiling that makes use of next-generation sequencing (NGS) technology. By advancing precision oncology, the test hopes to enhance patient outcomes..

Global Companion Diagnostics Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Technology, Indication, End User Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Technology:

  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • In-situ Hybridization (ISH)
  • Real-time PCR (RT-PCR)
  • Gene Sequencing
  • Other Technologies

By Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • Other Indications

By End User:

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • CROs
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Companion Diagnostics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Companion Diagnostics Market, by Technology, 2019-2029 (USD Billion)
    • 1.2.3. Companion Diagnostics Market, by Indication, 2019-2029 (USD Billion)
    • 1.2.4. Companion Diagnostics Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Companion Diagnostics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Companion Diagnostics Market Dynamics

  • 3.1. Companion Diagnostics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of Cancer
      • 3.1.1.2. Rising Regulatory Approvals of New Tests for Different Indications
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Drug Development and Associated Clinical Trials
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Co-development of Drug and Diagnostic Technology
      • 3.1.3.2. Favourable government support

Chapter 4. Global Companion Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Companion Diagnostics Market, by Technology

  • 6.1. Market Snapshot
  • 6.2. Global Companion Diagnostics Market by Technology, Performance - Potential Analysis
  • 6.3. Global Companion Diagnostics Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
  • 6.4. Companion Diagnostics Market, Sub Segment Analysis
    • 6.4.1. Immunohistochemistry (IHC)
    • 6.4.2. Polymerase Chain Reaction (PCR)
    • 6.4.3. In-situ Hybridization (ISH)
    • 6.4.4. Real-time PCR (RT-PCR)
    • 6.4.5. Gene Sequencing
    • 6.4.6. Other Technologies

Chapter 7. Global Companion Diagnostics Market, by Indication

  • 7.1. Market Snapshot
  • 7.2. Global Companion Diagnostics Market by Indication, Performance - Potential Analysis
  • 7.3. Global Companion Diagnostics Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
  • 7.4. Companion Diagnostics Market, Sub Segment Analysis
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Leukemia
    • 7.4.5. Melanoma
    • 7.4.6. Other Indications

Chapter 8. Global Companion Diagnostics Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Companion Diagnostics Market by End User, Performance - Potential Analysis
  • 8.3. Global Companion Diagnostics Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 8.4. Companion Diagnostics Market, Sub Segment Analysis
    • 8.4.1. Pharmaceutical & Biopharmaceutical Companies
    • 8.4.2. Reference Laboratories
    • 8.4.3. CROs
    • 8.4.4. Others

Chapter 9. Global Companion Diagnostics Market, Regional Analysis

  • 9.1. Companion Diagnostics Market, Regional Market Snapshot
  • 9.2. North America Companion Diagnostics Market
    • 9.2.1. U.S. Companion Diagnostics Market
      • 9.2.1.1. Technology breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Companion Diagnostics Market
  • 9.3. Europe Companion Diagnostics Market Snapshot
    • 9.3.1. U.K. Companion Diagnostics Market
    • 9.3.2. Germany Companion Diagnostics Market
    • 9.3.3. France Companion Diagnostics Market
    • 9.3.4. Spain Companion Diagnostics Market
    • 9.3.5. Italy Companion Diagnostics Market
    • 9.3.6. Rest of Europe Companion Diagnostics Market
  • 9.4. Asia-Pacific Companion Diagnostics Market Snapshot
    • 9.4.1. China Companion Diagnostics Market
    • 9.4.2. India Companion Diagnostics Market
    • 9.4.3. Japan Companion Diagnostics Market
    • 9.4.4. Australia Companion Diagnostics Market
    • 9.4.5. South Korea Companion Diagnostics Market
    • 9.4.6. Rest of Asia Pacific Companion Diagnostics Market
  • 9.5. Latin America Companion Diagnostics Market Snapshot
    • 9.5.1. Brazil Companion Diagnostics Market
    • 9.5.2. Mexico Companion Diagnostics Market
    • 9.5.3. Rest of Latin America Companion Diagnostics Market
  • 9.6. Rest of The World Companion Diagnostics Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Abbott Laboratories
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Agilent Technologies Inc.
    • 10.2.3. F.Hoffmann-La Roche Ltd
    • 10.2.4. Biomerieux SA
    • 10.2.5. Qiagen NV
    • 10.2.6. Siemens Healthcare Gmbh
    • 10.2.7. Thermo Fisher Scientific Inc.
    • 10.2.8. Danaher Corporation (Beckman Coulter Inc.)
    • 10.2.9. Almac Group
    • 10.2.10. Illumina Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption